Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients
Male
Amyloid
Humans; Male; Female; Aged; Alzheimer Disease/psychology; Brain/metabolism; Prospective Studies; Positron-Emission Tomography; Cognitive Dysfunction; Amyloid/metabolism; Amyloidogenic Proteins; Amyloid beta-Peptides/metabolism
psychology [Alzheimer Disease]
Tomografia
Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Consortium
metabolism [Amyloid beta-Peptides]
Amyloidogenic Proteins
info:eu-repo/classification/ddc/616.0757
Alzheimer Disease
Humans
Cognitive Dysfunction
ddc:610
Prospective Studies
Amyloid / metabolism
metabolism [Amyloid]
Original Investigation
Aged
Amyloid beta-Peptides
Amyloid beta-Peptides / metabolism
Brain
Alzheimer Disease / psychology
info:eu-repo/classification/ddc/618.97
Alzheimer, Malaltia d'
metabolism [Brain]
Positron-Emission Tomography
Brain / metabolism
Female
3-(3,5-dichlorophenyl)-1-methyl-2,5-pyrrolidinedione
DOI:
10.1001/jamaneurol.2023.0997
Publication Date:
2023-05-08T15:05:20Z
AUTHORS (328)
ABSTRACT
ImportanceAmyloid positron emission tomography (PET) allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this technique is currently not widely reimbursed because of the lack of appropriately designed studies demonstrating its clinical effect.ObjectiveTo assess the clinical effect of amyloid PET in memory clinic patients.Design, Setting, and ParticipantsThe AMYPAD-DPMS is a prospective randomized clinical trial in 8 European memory clinics. Participants were allocated (using a minimization method) to 3 study groups based on the performance of amyloid PET: arm 1, early in the diagnostic workup (within 1 month); arm 2, late in the diagnostic workup (after a mean [SD] 8 [2] months); or arm 3, if and when the managing physician chose. Participants were patients with subjective cognitive decline plus (SCD+; SCD plus clinical features increasing the likelihood of preclinical Alzheimer disease), mild cognitive impairment (MCI), or dementia; they were assessed at baseline and after 3 months. Recruitment took place between April 16, 2018, and October 30, 2020. Data analysis was performed from July 2022 to January 2023.InterventionAmyloid PET.Main Outcome and MeasureThe main outcome was the difference between arm 1 and arm 2 in the proportion of participants receiving an etiological diagnosis with a very high confidence (ie, ≥90% on a 50%-100% visual numeric scale) after 3 months.ResultsA total of 844 participants were screened, and 840 were enrolled (291 in arm 1, 271 in arm 2, 278 in arm 3). Baseline and 3-month visit data were available for 272 participants in arm 1 and 260 in arm 2 (median [IQR] age: 71 [65-77] and 71 [65-77] years; 150/272 male [55%] and 135/260 male [52%]; 122/272 female [45%] and 125/260 female [48%]; median [IQR] education: 12 [10-15] and 13 [10-16] years, respectively). After 3 months, 109 of 272 participants (40%) in arm 1 had a diagnosis with very high confidence vs 30 of 260 (11%) in arm 2 (P < .001). This was consistent across cognitive stages (SCD+: 25/84 [30%] vs 5/78 [6%]; P < .001; MCI: 45/108 [42%] vs 9/102 [9%]; P < .001; dementia: 39/80 [49%] vs 16/80 [20%]; P < .001).Conclusion and RelevanceIn this study, early amyloid PET allowed memory clinic patients to receive an etiological diagnosis with very high confidence after only 3 months compared with patients who had not undergone amyloid PET. These findings support the implementation of amyloid PET early in the diagnostic workup of memory clinic patients.Trial RegistrationEudraCT Number: 2017-002527-21
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (28)
CITATIONS (21)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....